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Pancreatic adenocarcinoma is currently the
fourth leading cause for cancer-related mortal-
ity. Stem cells have been implicated in pancre-
atic tumor growth, but the specific role of these
cancer stem cells in tumor biology, including
metastasis, is still uncertain. We found that
humanpancreatic cancer tissue contains cancer
stem cells defined by CD133 expression that
are exclusively tumorigenic and highly resistant
to standard chemotherapy. In the invasive front
of pancreatic tumors, a distinct subpopulation
of CD133+ CXCR4+ cancer stem cells was iden-
tified that determines the metastatic phenotype
of the individual tumor. Depletion of the cancer
stem cell pool for these migrating cancer stem
cells virtually abrogated the metastatic pheno-
type of pancreatic tumors without affecting
their tumorigenic potential. In conclusion, we
demonstrate that a subpopulation of migrating
CD133+ CXCR4+ cancer stem cells is essential
for tumor metastasis. Strategies aimed at mod-
ulating the SDF-1/CXCR4 axis may have impor-
tant clinical applications to inhibit metastasis of
cancer stem cells.
INTRODUCTION
Pancreatic adenocarcinoma is currently the fourth leading
cause for cancer-related mortality. The mortality rate ap-
proaches 100% due to the propensity for early metastatic
spread and because the disease is highly resistant to radi-
ation and chemotherapy. Despite increasing knowledge in
tumor biology, the treatment efficacy in pancreatic can-
cers has not improved significantly over the past decade.
Although the first-line agent gemcitabine has produced
clinical response such as reduced pain and weight gain
(Matano et al., 2000), the prognosis remains dismal with
a 5 year survival rate of 1%–4% and a median survival
period of 4–6 months (Ahlgren, 1996; Jemal et al., 2004;
Rosenberg, 1997; Rothenberg et al., 1996; Warshaw andCell SFernandez-del Castillo, 1992). More recently, however,
increasing evidence suggests that stem cells may play a
decisive role not only in the generation of complex multi-
cellular organisms but also in the development and pro-
gression of tumors (Clarke et al., 2006; Jordan et al.,
2006). Cells bearing stem cell properties may represent
an integral part of the development and perpetuation of
various human cancers (Al-Hajj et al., 2003; Kim et al.,
2005; O’Brien et al., 2007; Ricci-Vitiani et al., 2007; Singh
et al., 2004). The current consensus definition describes
a cancer stem cell (CSC) as a cell within a tumor that is
able to self-renew and to produce the heterogeneous
lineages of cancer cells that comprise the tumor (Clarke
et al., 2006). The implementation of this concept explains
the use of alternative terms in literature, such as ‘‘tumor-
initiating cell’’ and ‘‘tumorigenic cell’’ to describe putative
CSC (Al-Hajj et al., 2003; Kim et al., 2005; O’Brien et al.,
2007; Ricci-Vitiani et al., 2007; Singh et al., 2004).
The stem cell hypothesis has recently been explored in
pancreatic cancer (Li et al., 2007). However, CSCmay not
only be associated with tumor initiation and growth but
may also play a crucial role in tumor metastasis. Indeed,
if CSC represent the only cell population with tumor-
initiating potential, one would hypothesize that solely
CSC are capable of generating tumor metastases. In the
present study, we provide multiple lines of evidence for
the crucial role of CSC in pancreatic tumor growth and,
even more importantly, define a subpopulation of migrat-
ing CSC in tumor metastasis.
RESULTS
Identification and Characterization of Human
Pancreatic CSC
In a first step, we aimed to identify pancreatic CSC in tis-
sue samples derived from patients with pancreatic cancer
(patient characteristics are depicted in Table S1 in the
Supplemental Data available with this article online).
CSC were identified by means of the surface marker
CD133, which is expressed by normal and malignant
stem cells of the neural, hematopoietic, epithelial, and
endothelial lineages (Fargeas et al., 2003; Yin et al.,
1997). Flow cytometry demonstrated presence of a rare
CSC population (Figure 1A, left and middle panels).tem Cell 1, 313–323, September 2007 ª2007 Elsevier Inc. 313
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Cancer Stem Cells in Tumor MetastasisFigure 1. Detection of CD133+ Cells in Patient-Derived Pancreatic Cancer Samples
(A) To assess the number of CD133+ cells, digested tissue samples were either stained for CD133 and analyzed by flow cytometry or paraffin sections
were stained for CD133 (red) and counterstained with DAPI (blue). Representative examples from primary tumors of two individual patients are
provided in the left (flow cytometry) and right (histology) panels. Three-dimensional reconstruction of a tissue section is provided in the right lower
panel. Quantification of the flow cytometry data is shown in the middle panel (n = five analyzed patients).
(B) Immunohistological staining for the epithelial marker cytokeratin (dark red) and counterstaining with hemalaun illustrates the invasive front in a
patient with pancreatic carcinoma. Single cells positive for cytokeratin are shown in high magnification in the right panel.
(C) An overview of the analyzed section was obtained by transmission light microscopy. Detailed analysis of CSC located in this representative
invasive front: double staining for cytokeratin (green) and CD133 (red) revealed that a large number CD133+ cells are located in the border zone of
the tumor and are rarely present in structures with epithelial differentiation but rather reside as single cells in the infiltrated stromal tissue.314 Cell Stem Cell 1, 313–323, September 2007 ª2007 Elsevier Inc.
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Cancer Stem Cells in Tumor MetastasisConsistently, histological analysis revealed that CD133+
CSC were anatomically localized in the bulk tumor
(Figure 1A, right panel). To more thoroughly investigate
CD133+ cells in the invasive border zone of pancreatic
cancer samples, we analyzed the invasive front in serial
pancreatic cancer sections by staining for cytokeratin.
As illustrated in Figure 1B, the invasive front is character-
ized by disseminated cytokeratin-positive tumor cells. All
seven samples from patients with pancreatic cancer re-
producibly demonstrated the presence of rare CD133+
cells in these areas with histological evidence for cell dis-
semination (Figure 1C). CD133+ cells were often found in
close proximity to more differentiated epithelial cells but
were essentially negative for the epithelial marker cytoker-
atin (Moll, 1998). In contrast, CD133 expression in healthy
pancreatic tissues was a very rare event (barely detect-
able upon extensive analysis of histological sections
with a mean of 0.27 ± 0.52 cells per high-power field
[= 0.021 mm2]) as compared to tumor tissue (3.60 ± 2.58
cells per high-power field) (Figure 1D). The increased num-
ber of CD133+ cells in cancer tissue most likely results
from their oncogenic transformation. Disseminated tumor
cells play a critical role in tumor metastasis, and migrating
CSC may represent a specific subset of CSC. Because
stromal cell-derived factor 1 (SDF-1) is an important medi-
ator in cell migration, we investigated the expression of its
specific receptor CXCR4 in CSC. Indeed, costaining for
CXCR4 indicated that CD133+ cells in the invasive front
strongly express CXCR4 (Figure 1E), whereas CXCR4 ex-
pression in CD133+ cells of the bulk tumor was rarely
found. These results already suggest a potential role of
CXCR4+ CSC in tumor dissemination.
In a further step, we evaluated the tumorigenic potential
of isolatedpancreaticCD133+CSC.Specifically,we inves-
tigated the ability of tumor-derived CD133+ and CD133
cells to orthotopically engraft and give rise to pancreatic
tumors in athymic mice. CD133+ CSC were isolated by
magnetic bead sorting, which resulted in a considerable
enrichment of CD133+ cells (regular purity > 90%) and,
even more importantly, a highly effective negative selec-
tion (purity > 99.8%) of CD133 cells (Figure 2A). Potential
contamination of the CD133+ cell population by hemato-
poietic and endothelial progenitors was excluded by flow
cytometry. CD133+ cells were only rarely positive for the
panhematopoietic marker CD45 (<0.5%), and fewer than
2% were putative CD31+ endothelial progenitors (Fig-
ure 2B, left panel). CD133+ cells did not express the epithe-
lial differentiation marker cytokeratin (Figure 2B, right
panel). In a mouse model of pancreatic cancer, as many
as 106 patient-derived CD133 pancreatic cancer cells
did not induce tumor formation. In contrast, 106 unsepa-
rated cells or as few as 53 102 CD133+ cells resuspended
in Matrigel generated visible tumors after 3 weeks (Fig-
ure 2C; Figure S1A). These data indicate that cells capableCell Sof initiating pancreatic cancer are highly enriched with
a CD133+ cell population. Interestingly, despite the higher
number of CD133+ cells present in 106 unseparated cells
(mean 1.83 104 cells), tumor formation following injection
of purified CD133+ cells was faster andmore efficient than
tumor formation obtained with the total pancreatic cancer
cell population (Figure 2C). We observed a close correla-
tionbetween thepercentage ofCD133+ cells in theprimary
tumor as assessed by flow cytometry and the tumori-
genicity of the unfractionated cells (r = 0.92; p < 0.05)
(Figure S1B). Additionally, immunohistochemistry and
subsequent microscopic analysis revealed that tumor
xenografts derived from CD133+ cells consistently repro-
duced the primary tumor at the histological level (Fig-
ure 2D). Thus, the tumorigenic population in pancreatic
cancer is restricted to CD133+ cells, which can reproduce
the original tumor in permissive recipients.
To investigate whether CD133+ pancreatic cancer cells
display long-term tumorigenic potential, we evaluated
their ability to generate tumors after serial transplanta-
tions. For this purpose, 5 3 102 CD133+ or 106 CD133
cells from primary tumor xenografts were transplanted
into secondary mice. Indeed, injected CD133+ tumor cells
engrafted and generated tumors that grew rapidly and
required the mouse to be sacrificed within 3 weeks
(Figure 2C). Additionally, CD133+ tumor cells obtained
from similar CD133+-derived secondary xenografts were
subsequently transplanted into third-generation mice.
The implanted CSC were negative for cytokeratin,
whereas the developing tumors also contain cytokera-
tin positive differentiated tumor cells as their progeny
(Figure 2D). Moreover, tumor morphology was indistin-
guishable from tumors generated by unfractionated cells.
During the in vivo passaging, CD133+ cells did not lose
their tumorigenic potential but instead increased their
aggressiveness, as indicated by faster tumor growth
(Figure 2E). This was not related to a higher content of
CD133+ CSC but may be related to in vivo selection of a
highly tumorigenic subpopulation of CD133+ cells (Fig-
ure S1C). Thus, the CD133+ cell population resident in
the pancreatic tumor mass is able to generate serial xeno-
grafts showing a virtually unlimited growth potential.
In Vitro Expansion of Human Pancreatic CSC
To be able to study the cell biology of CSC more exten-
sively, we investigated whether human pancreatic cancer
cell lines also contain CSC recapitulating the features of
primary cells isolated from patients with pancreatic can-
cer. Flow cytometric analysis revealed that the highly
aggressive human pancreatic cancer cell line L3.6pl also
contains a reproducible number of CD133+ CSC (Fig-
ure 3A). Orthotopic implantation of MACS-isolated cells
revealed that as few as 103 CD133+ L3.6pl cells were
capable of inducing tumor formation (Figure 3B), whereas(D) Normal pancreatic tissue also contains very few CD133+ cells. Double staining for CD133 (red) and cytokeratin (green) showed a stem cell only in
every third microscopic field.
(E) Triple staining for CD133 (red), CXCR4 (white), and cytokeratin (green) identifies a distinct subpopulation of CSC in the invasive front.
Error bars represent standard deviations.tem Cell 1, 313–323, September 2007 ª2007 Elsevier Inc. 315
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Cancer Stem Cells in Tumor MetastasisFigure 2. Tumorigenic Potential of
CD133+ Patient-Derived Pancreatic
Cancer Cells
(A) CD133+ cells were isolated from freshly
resected tumors by magnetic bead selection
using the CD133/1 antibody. Samples were
then stained with the CD133/2 antibody and
analyzed by flow cytometry indicating excel-
lent depletion for CD133+ CSC in the negative
fraction (left panel) as well as high enrichment
for CD133+ CSC in the positive fraction (right
panel).
(B) Flow cytometry for the pan-endothelial
marker CD31 and the pan-leukocyte marker
CD45 was performed to detect potential con-
tamination of isolated cells with endothelial or
hematopoietic progenitors (left panel). Staining
for cytokeratin revealed no expression in CSC
(right panel). Experiments were performed in
duplicates.
(C) After MACS isolation of first-generation hu-
man pancreatic cancer cells, we orthotopically
implanted CD133+, CD133, or the unfractio-
nated cells into the pancreas of NMRI nu/nu
mice. Only CD133+ and the entire tumor cell
population were capable of inducing tumor
formation. Isolation of second- and third-
generation tumor cells from transplanted
mice revealed similar results (n = seven ana-
lyzed patients; experiments were performed
in triplicates).
(D) Histological analysis of first-generation
tumors (upper panel) and third-generation
tumors (lower panel) by staining for cytokeratin
and counterstaining for hemalaun revealed
that although implanted CSC were negative
for cytokeratin, the developing tumors also
contain cytokeratin-positive differentiated
tumor cells as their progeny.
(E) Tumor size increased using later genera-
tions of tumor cells regardless of whether iso-
lated CSC or the entire tumor cell population
was injected. Experiments were performed at
least in duplicates. Asterisks indicate p < 0.05
versus first generation.
Error bars represent standard deviations.as many as 106 CD133 L3.6pl cells failed to do so.
Retransplantation of isolated tumor cells also resulted in
reproducible tumor formation in secondary recipients.
These data indicate that the L3.6pl cell line is a suitable
model to study the biology of pancreatic CSC.
Because normal and neoplastic stem cells from neural
and epithelial organs can be expanded as sphere-like
cellular aggregates (Dontu et al., 2003; Singh et al., 2004)
in serum-free medium containing EGF and FGF-2, we cul-
tivated the L3.6pl pancreatic cancer cells using culture
conditions (ultra low adhesion plates) that favor the prolif-
eration of undifferentiated cells. Within 2 to 3 weeks of
culture, we obtained pancreatic spheres formed by ag-
gregates of growing undifferentiated CD133+ cells (Fig-
ure S3Cc). CD133 pancreatic cancer cells invariably
died in such serum-free conditions but could grow for sev-
eral weeks in serum-containing medium. The standard
culture of unselected cells allowed the persistence of the316 Cell Stem Cell 1, 313–323, September 2007 ª2007 ElsevieCD133+ population at low levels (mean 0.8 ± 0.3%).
When CD133+ cells were grown as pancreatic spheres,
these cells remained CD133+ and expressed negligible
amounts of cytokeratin. In contrast, the vast majority of
cells obtained under standard culture conditions did ex-
press cytokeratin (data not shown). Single cells obtained
from these dissociated spheres could be clonally ex-
panded. To determine the differentiation potential of these
CD133+ cells, tumor spheres were cultivated without EGF
and FGF-2 in the presence of 10% serum. After several
days of culture, cells differentiated into large adherent
cells (Figure S3Cc). Upon differentiation, pancreatic can-
cer cells expressed cytokeratin and acquired a morphol-
ogy closely resembling the major pancreatic cancer cell
population. Therefore, the ability to grow exponentially
and the lack of cytokeratin expression as well as the
tumorigenic potential suggest that CD133+ pancreatic
spheres are aggregates of primitive cancer cells.r Inc.
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Cancer Stem Cells in Tumor MetastasisFigure 3. Human Pancreatic CSC De-
rived from Pancreatic Cancer Cell Lines
(A) The established human pancreatic cancer
cell line L3.6pl also contained a distinct popu-
lation of CD133+ cells under standard culture
conditions accounting for 1% to 2% (right
panel) as determined by flow cytometry. Iso-
type control ruled out unspecific binding of epi-
topes (left panel). Experiments were performed
in triplicates.
(B) After MACS isolation of first-generation
L3.6pl cells, we orthotopically implanted
CD133+ cells and CD133 cells into the pan-
creas of mice, respectively. Only CD133+ cells
or the total tumor cell population were capable
of inducing tumor formation (nR 6). Isolation of
second-generation L3.6pl cells showed similar
results concerning CD133 cells (0%), but
caused tumor formation in all the mice
receiving CD133+ cells (nR 4).
(C) Flow cytometry was used for cell-cycle
analysis of CD133+ and CD133 L3.6pl cells
before and after exposure to gemcitabine.
Cells were stained for 7-AAD as marker for
apopotosis and for BrdU as marker for DNA
synthesis. Cells in S phase are depicted in
gate R4, and apoptotic cells are depicted in
gate R2. Baseline data are provided in the left
panel. Cells were then treated with gemcita-
bine for 24 hr (middle panel) followed by 24 hr
of recovery after withdrawal of gemcitabine
(right panel).
(D) Quantification of the cell-cycle analysis. > >
indicates withdrawal of gemcitabine for 24 hr.
Results are based on three independent ex-
periments. Asterisks indicate p < 0.01 versus
control.
Error bars represent standard deviations.Resistance of Human Pancreatic CSC
to Standard Chemotherapy
Pancreatic cancers are fundamentally resilient to treat-
ment because the malignant cells survive chemotherapy.
Because CSC may play a crucial role in treatment resis-
tance, we performed cell-cycle analyses by flow cytome-
try. Both CD133+ and CD133 cells were exposed to the
standard chemotherapeutic agent gemcitabine. We found
that CD133+ cells showed dramatic drug resistance to
gemcitabine compared to autologous CD133 cells (Fig-
ures 3C and 3D). Prolonged treatment with gemcitabine
favored the survival of CSC so that after 5 days about
50% of the cultivated cells were CSC (Figure 4A). Consis-
tently, primary tumor cells from patients with pancreatic
cancer also exhibit a strong resistance to gemcitabine
(Figure S2). To demonstrate the in vivo relevance of these
findings, we analyzed tumor samples from mice bearing
pancreatic cancer after injection of 106 L3.6pl cells and re-
ceiving either vehicle or gemcitabine treatment (biweekly
with 125 mg/kg gemcitabine by i.p. administration for 21
days). Although the tumors were significantly smaller
compared to vehicle-treated mice (100.5 ± 36.4 versusCell S183.8 ± 66.9 mm3; p < 0.05), a profound enrichment of
CD133+ CSC had occurred (Figure 4B).
Role of Human Pancreatic CSC
in Tumor Metastasis
On the basis of the provided histological evidence for the
existence of CXCR4+ CSC in the invasive front of human
tumor specimens (Figure 1E), we hypothesized that a spe-
cific subset of CXCR4+ CD133+ CSC plays a crucial role
in tumor metastasis. For this purpose we used a model
involving two related human pancreatic cancer cell lines
with opposing metastatic activity. The L3.6pl cells are de-
rived from their parental FG cells by multiple in vivo cycles
to select for highly metastatic cells (Bruns et al., 1999).
While quantitative differences in the CSC content between
these two related cell lines were detectable only under
certain culture conditions (data not shown), the qualitative
differences in the CSC characteristics were highly consis-
tent and indeed remarkable. While L3.6pl-derived CD133+
CSC displayed a strong migratory activity, FG-derived
CD133+ CSC showed significantly lower invasive activity.
Intriguingly, only the L3.6pl-derived CD133+ CSCtem Cell 1, 313–323, September 2007 ª2007 Elsevier Inc. 317
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Cancer Stem Cells in Tumor MetastasisFigure 4. Standard Chemotherapy En-
riches for CSC
(A) Prolonged treatment of L3.6pl cell culture
with gemcitabine favored survival of CD133+
CSC, with the result of up to 50% of the entire
cell count being CD133+ (nR 4).
(B) In vivo L3.6pl-derived tumor xenograft ex-
periments showed that gemcitabine resulted
in a significant enrichment for CD133+ cells.
Gemcitabine (biweekly 125 mg/kg i.p.) or vehi-
cle treatment was initiated 9 days after ortho-
topic tumor cell implantation. CSC content
was determined after 3 weeks of treatment
by flow cytometry. Representative images (up-
per panel) and the quantification (lower panel)
are shown. Asterisks indicate p < 0.01 versus
control; nR three animals per group).
Error bars represent standard deviations.predominantly expressed the CXCR4 receptor, and their
strong migratory activity was primarily mediated by
CXCR4 (Figure 5A). Similar findings were observed for
several other pancreatic cancer cell lines as well as pri-
mary specimens from patients with pancreatic cancer or
colon cancer (Figure S3). MiaPaCa cells, a cell line with
a very invasive growth pattern, also contained a distinct
subpopulation of migrating CSC, and the migratory activ-
ity of these cells was clearly dependent on CXCR4
(Figure 5B). Indeed, SDF-1 as the specific ligand for the
CXCR4 receptor was the most potent inductor of migra-
tion for CD133+ CSC, whereas c-Met, which is activated
by the hepatocyte growth factor (HGF), was not detect-
able on pancreatic cancer cells (Figure 6A) and indeed
did not show a significant induction of cell migration as
compared to control (data not shown). These observa-
tions indicate that migration of CD133+ cells is primarily
mediated through the SDF-1/CXCR4 system.
On the basis of these data, we hypothesized that the
phenotypic differences between metastatic L3.6pl cells
and their parental FG cells are primarily due to the pres-
ence of highly invasive CD133+ CXCR4+ CSC in the
L3.6pl cancer cell population. To test this hypothesis, we
isolated from L3.6pl cells both CD133+ CXCR4+ cells
and CD133+ CXCR4 cells to high purity using high-speed
FACS (Figure 6B) and orthotopically injected into athymic318 Cell Stem Cell 1, 313–323, September 2007 ª2007 Elseviemice either 53 102 tumor-initiating CD133+ CXCR4 cells
together with 5 3 102 migrating CD133+ CXCR4+ cells
(CXCR4+) or only 103 tumor-initiating CD133+ CXCR4
cells (CXCR4). Both groups showed similar tumor devel-
opment (262 ± 64 versus 256 ± 73mm2; p = 0.75). Flow cy-
tometric analysis of portal vein blood samples following
development of tumors identified only in the CXCR4+
group a reproducible population of circulating CD133+
CXCR4+ CSC (0.04 ± 0.03 of gated cells) (Figure 6C),
whereas in the CXCR4 group, no CD133+ CSC, either
CXCR4+ or CXCR4, could be detected in the circulating
blood. These data support the hypothesis that CXCR4+
CD133+ CSC represent a distinct invasive CSC population
and cannot be derived from CD133+ CXCR4 CSC. Tu-
mors were removed by partial resection of the pancreas
and complete splenectomy to allow isolated growth of
metastases. Another 2 weeks later, thorough macro-
scopic and microscopic analysis of the livers revealed
that only mice in the CXCR4+ group developed liver me-
tastases, whereas mice receiving CD133+ CXCR4 cells
did not show any trace of liver metastasis (Figure 6D). To
provide further evidence that inhibition of CXCR4+ CSC
abrogates tumor metastasis, we performed a study us-
ing continuous pharmacological inhibition of the CXCR4
receptor by AMD3100 and, thus, permanent inhibition
of tumor (stem) cell migration. Indeed, we found thatr Inc.
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Cancer Stem Cells in Tumor MetastasisFigure 5. Identification of Migrating
Pancreatic CSC
(A) The migratory capacity of L3.6pl and FG
cells was assessed in a modified Boyden
chamber assay. Prior to the experiment, cells
were separated into CD133+ and CD133 cells
by MACS isolation. The involvement of the
CXCR4 receptor was determined by simulta-
neous administration of the CXCR4 neutraliz-
ing antibody. Single asterisk indicates p <
0.01 versus CD133 cells. Double asterisk indi-
cates p < 0.01 versus no CXCR4 neutralizing
antibody.
(B) The migratory activity of MiaPaCa cells
in the presence or absence of CXCR4 neutral-
izing antibodies is shown in the left panel. In the
lower Boyden chamber, a dramatic increase
in the number of CXCR4+ migrating CSC was
observed (right upper panel) that was abro-
gated in the presence of CXCR4 neutralizing
antibodies (right lower panel). Asterisk indi-
cates p < 0.05 versus iso control mAb.
Error bars represent standard deviations.concomitant AMD3100 treatment significantly reduced
tumormetastasis (Figure S4A). To demonstrate the clinical
relevance of our experimental findings, we performed
additional studies in patients with pancreatic cancer. In-
triguingly, we found that tumor cells with a high number
of CXCR4+ CSC showed a markedly increased migratory
activity and that these patients suffered from a more
advanced metastatic disease (Figures S4B and S4C).
DISCUSSION
Here we demonstrate that tumorigenic pancreatic cells
are included in a rare population of undifferentiated cells
that express CD133 (Fargeas et al., 2003; Yin et al.,
1997). Freshly isolated patient-derived CD133+ pancreatic
CSC were highly tumorigenic, and as few as 500 cells
were capable of inducing orthotopic tumor formation in
athymic mice. In contrast, as many as 106 CD133 tumor
cells did not result in any tumor formation. Most impor-
tantly, we show here that CSC do not represent a homo-
geneous population of tumor-initiating cells. Instead, we
define a subpopulation of migrating CSC that are charac-
terized by expression of the CXCR4 receptor and are crit-
ically involved in tumor metastasis. Indeed, elimination of
this subpopulation of CSC virtually abrogated the meta-
static activity of pancreatic cancer cells.
Our data are well in line with the CSC hypothesis that
suggests that tumors are generated and maintained by
a small subset of undifferentiated cells with the ability to
self-renew and differentiate into the bulk tumor population
(Clarke et al., 2006; Dalerba et al., 2007; Dick, 2005; Kim
et al., 2005; O’Brien et al., 2007; Ricci-Vitiani et al.,
2007; Singh et al., 2004). As in other cancers such as leu-Cell Skemia, breast, brain, and colon cancer, stem and early
progenitor cells also seem to be the target of oncogenic
transformation in pancreatic cancer. It is certainly possible
that CSC arise by mutations from normal stem cells. On
the other hand, several lines of evidence suggest that
CSC could also arise from mutated progenitor cells (Pas-
segue et al., 2003; Prindull, 2005). However, to become a
CSC, a progenitor cell must acquire mutations that cause
it to regain the property of self-renewal. Indeed, many
studies have demonstrated that the expression of stem-
cell-like properties in tumor cells does not necessarily
suggest that these cells originated from stem cells. In
experimental settings, the expression of cooperating
oncogenes in lineage-restricted progenitor cells can yield
tumors with the cytopathological characteristics of highly
malignant tumors (Barnett et al., 1998). These studies sug-
gest that CSC are not necessarily derived from bona fide
tissue-specific stem cells but instead may arise from a
committed progenitor cell that reacquired stem-cell-like
properties during oncogenic transformation. At the
moment, the state of knowledge of tissue stem cells and
progenitor cells residing in the pancreas still needs to be
markedly advanced to permit side-by-side analysis of
these cell populations with pancreatic tumor cells before
this issue can be solved.
CD133 is expressed by normal tissue-resident as well
as hematopoietic stem cells (Peichev et al., 2000; Uchida
et al., 2000; Yin et al., 1997). As demonstrated for hema-
topoietic and endothelial progenitors, CD133 is also
expressed on early progenitors but usually is no longer
detectable upon differentiation (Peichev et al., 2000). In
tumor cells, CD133 has been used for the identification
of a subpopulation of highly tumorigenic cells astem Cell 1, 313–323, September 2007 ª2007 Elsevier Inc. 319
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Cancer Stem Cells in Tumor MetastasisFigure 6. Role of Migrating Pancreatic CSC in Tumor Metastasis
(A) Expressionof thehepatocytegrowth factor receptorc-Met and theSDF-1 receptorCXCR4onCD133 (leftpanel) andCD133+L3.6pl cells (rightpanel).
(B) High-speed FACSwas used to deplete CD133+ L3.6pl CSC for the distinct population of CD133+ CXCR4+migratingCSC (gate R6) followedby ortho-
topic implantation of either the complete CSC pool or CSC depleted for CD133+ CXCR4+ into the pancreas of NMRI nu/nu mice.
(C) Portal vein blood was investigated for the presence of circulating migrating L3.6pl CSC characterized by double staining for CD133 and CXCR4.
(D) Histological analysis of the liver for metastatic lesions was performed by staining for cytokeratin (red) and counterstaining with hemalaun. The meta-
static statusof themice in the twogroups isprovidedseparately formacroscopic (black)andmicroscopic (hatched) evidence formetastasis (left panel) (n=
five per group). Representative images are from amouse receiving CD133+ L3.6pl CSC depleted for CD133+ CXCR4+ migrating CSC and a mouse also
receiving CD133+ CXCR4+ migrating CSC (right panel).demonstrated for neural cancers and, more recently, also
for cancers of the colon (O’Brien et al., 2007; Singh et al.,
2004). However, it is not expressed on tumor cells upon
their differentiation. Thus, the present data from pancre-320 Cell Stem Cell 1, 313–323, September 2007 ª2007 Elseviatic cancer are well in line with these earlier findings as
we identified a subpopulation of CD133+ cells that bear
self-renewal capacity as they can be clonally expanded,
are exclusively tumorigenic, and are able to differentiateer Inc.
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Cancer Stem Cells in Tumor Metastasisinto CD133 tumor cells. A very recent study in pancreatic
cancer has utilized amarker combination of CD44+ CD24+
ESA+ for the identification of CSC (Li et al., 2007). By flow
cytometry analysis, we showed that these two popula-
tions overlap but are not identical.
CSC are likely to undergo symmetric and asymmetric
divisions in vivo, which results in the expansion of the
tumorigenic cell population while producing a progeny of
more differentiated cells that constitute the prevalent pop-
ulation of the tumor cell mass (Dalerba et al., 2007). It is
becoming increasingly evident that cancer treatments
that fail to eliminate CSCmay allow regrowth of the tumor.
Indeed, in cases in which bulk disease is eradicated and
chemotherapy is given, only to be followed by a relapse,
a plausible explanation is that the CSC have not been de-
stroyed completely. In the present experiments, we found
substantial resistance of pancreatic CSC to standard che-
motherapy. Even very high concentrations of gemcitabine
in vitro (up to 100 mg/ml) were not capable of inducing
significant apoptosis and/or cell death in CSC, whereas
virtually all other tumor cells were eradicated within a few
days of gemcitabine treatment. Consistently, in vivo ad-
ministration of gemcitabine in amousemodel of orthotopic
pancreatic cancer resulted in amarked relative enrichment
for pancreatic CSC as primarily nontumorigenic CD133
cells were eliminated. Therefore, the further molecular
characterization of the tumorigenic CD133+ pancreatic
cancer cells identified in the present study will be crucial
for the development of new therapeutic strategies to
cope with this challenge in the future. Most importantly,
the demonstrated possibility of expanding pancreatic
CSC in vitro has considerable therapeutic implications
for the evaluation of drug efficacy. This ability to maintain
and even expand tumorigenic pancreatic cancer cells
in vitro should be exploited for further preclinical studies.
However, the cancer stem cell concept will have to con-
sider the existence of two forms of CSC in tumor progres-
sion, a stationary as well as an invasive CSC. The station-
ary CSC are still embedded in the epithelial tissue and are
probably already active in benign precursor lesions (He
et al., 2007). However, these stationary CSC cannot dis-
seminate. In contrast, invasive CSC are located predomi-
nantly at the tumor-host interface. These invasive CSC,
which combine the two perhaps most decisive traits,
stemness and invasiveness, hold important clues for the
further understanding of malignant progression. These
cells have also been termed migrating CSC, and, indeed,
we here provide evidence for their existence in pancreatic
cancer and their important role inmetastasis. Invasion and
metastasis are not random processes but are highly organ
specific and pathophysiologically organized involving
multiple steps and numerous interactions between cancer
cells and the host. The SDF-1/CXCR4 axis was originally
detected in leukocytes being responsible for trafficking
and homing of hematopoietic progenitors (Loetscher
et al., 2000). Homozygous CXCR4-deficient mice are le-
thal, displaying diverse deformities (Zou et al., 1998). Re-
cent reports suggest that CXCR4 may well be a key regu-
lator of tumor invasiveness leading to local progressionCell Stand tumor metastasis (Burger and Kipps, 2006). Hyp-
oxia-inducible factor (HIF-1) overexpression or functional
loss of the HIF-suppressing pVHL-protein (vonHippel-Lin-
dau) result in CXCR4 expression in renal cell carcinoma,
further supporting a potential role of increased CXCR4 ex-
pression in tumor spread (Staller et al., 2003; Zagzag et al.,
2005). From a clinical perspective, enhanced CXCR4 ex-
pression is associated with poor outcome in renal cancer
(Zagzag et al., 2005). SDF-1, the specific ligand of CXCR4,
is strongly expressed in lung, liver, bone marrow, and
lymph nodes, sites that are commonly affected by pancre-
atic cancer metastases. In analogy to the directed homing
of leukocytes, these gradients of SDF-1 may attract tumor
cells and regulate proliferation and invasion at specific
metastatic sites (Bachelder et al., 2002; Muller et al.,
2001; Schneider et al., 2002), which has been shown for
pancreatic cancer in a mouse model of experimental me-
tastasis (Saur et al., 2005). This SDF-1/CXCR4 system
also appears to regulate metastasis of other cancer types,
including cancers of colon, lung, and breast (Kucia et al.,
2005; Muller et al., 2001; Zeelenberg et al., 2003). Consis-
tently, we demonstrate that the migration of invasive CSC
is primarily mediated through activation of the CXCR4
receptor. It is most intriguing that in an in vivo model of
orthotopic pancreatic cancer, implantation of a CSC pop-
ulation, which was depleted for these migrating CSC
(CD133+ CXCR4+), virtually abrogated the metastatic
activity of the developing tumors. These data demon-
strate for the first time that in the utilized in vivo system a
specific CD133+ CXCR4+ CSC subpopulation is the only
population responsible for tumor metastasis. Together
with data emerging from other tumor entities, this creates
a considerable interest in the specific targeting and erad-
ication of CSC (Clarke et al., 2006; Dalerba et al., 2007).
EXPERIMENTAL PROCEDURES
Human Pancreatic Cancer Cells
and Culture Conditions
We used a highly metastatic cell line (L3.6pl) isolated after successive
cycles of selections in nude mice (Bruns et al., 1999). The original
COLO 357 human pancreatic cancer cell line established from a celiac
lymph node metastasis of well-differentiated, mucin-containing pan-
creatic cancer cells was injected into the spleen of nudemice to isolate
liver metastases designated as the L3.3 line. We then orthotopically
injected the L3.3 cells into the pancreas of athymic mice and isolated
liver metastases, which we designated as L3.4pl (pancreas-liver). After
two additional orthotopic injection-selection cycles, we isolated the
cells designated as L3.6pl, which produced spontaneous liver metas-
tasis at a significantly higher incidence than the original COLO 357 cells
(here referred to as FG cells). The highly metastatic L3.6pl human pan-
creatic cancer cells as well as the parental FG cells were maintained
in DMEM medium (Invitrogen, Karlsruhe, Germany) supplemented
with 12% fetal calf serum (Biochrom, Berlin, Germany), glutamax
(Invitrogen), sodium pyruvate, nonessential amino acids, and penicil-
lin-streptomycin mixture, and a 2-fold vitamin solution (all from PAN,
Aidenbach, Germany). Adherent monolayer cultures were maintained
on plastic dishes and incubated at 37C and 5% CO2. Cultures were
maintained for less than 6 weeks after recovery from frozen stocks.
To propagate the CSC fraction of the tumor cells, culture conditions
favoring proliferation of undifferentiated cells were selected. To avoid
adhesion and subsequent differentiation of CSC, we cultivated theem Cell 1, 313–323, September 2007 ª2007 Elsevier Inc. 321
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described, for at least 14 days and until formation of spheres could
be observed (Denham et al., 2006). Cells were grown in a NS-A basal
serum-free medium (Euroclone, Irvine, UK), containing 2 mM L-gluta-
mine, 0.6% glucose, 9.6 mg/ml putrescine, 6.3 ng/ml progesterone, 5.2
ng/ml sodium selenite, 0.025 mg/ml insulin, 0.1 mg/ml transferrin
sodium salt (Sigma, St Louis, MO), and supplemented with 20 ng/ml
EGF (PeproTech EC, London, UK) and 10 ng/ml FGF-2 (PeproTech
EC). Cultures of differentiated tumor cells were obtained from tumor
spheres after removal of growth factors and addition of 5% FCS and
cultured for 7 days.
Prospective Isolation of Putative CSC
CSCwere isolated bymagnetic bead sorting using theMidiMACS sys-
tem (Miltenyi Biotech). For this purpose, tumor cell suspensions from
solid tumors were prepared by mechanical dissociation and incubated
with collagenase type IV (Sigma) for 1 hr under continuous shaking at
37C. In other experiments, cultured tumor cells were trypsinized,
washed, and resuspended in PBS (Invitrogen). Cells were then incu-
bated with a monoclonal CD133 antibody labeled with MicroBeads
(Miltenyi Biotech) for 30 min at 4C, and CD133+ cells were enriched
using a MidiMACS magnet and MS columns (Miltenyi Biotech). All
MACS procedures were performed according to the manufacturer’s
instructions. The purity of isolated cells was determined by standard
flow cytometry analysis using an APC-labeled antibody against human
CD133/2 (clone 293C3). The purity of isolated CD133+ CSC regularly
exceeded 90%. For fluorescence activated cell sorting (FACS), cells
were stained with APC-labeled CD133 antibodies and sorted by using
a modular MoFlo device and Summit software (Cell Sorting Facility of
the Institute of Molecular Immunology at Helmholtz Center for Environ-
ment and Health, Munich, Germany).
Antibodies
To characterize pancreatic CSC, the following antibodies were used:
anti-CD133/1-APC (clone AC133) for cell isolation and characterization
and anti-CD133/2-APC (clone 293C3; both from Miltenyi Biotech,
Bergisch Gladbach, Germany) for determination of the purity of the
isolated cells; anti-c-Met-FITC, anti-CD24-FITC, anti-CD31-PE, or
anti-CD44-PE (all from ebiosciences San Diego, CA); anti-CD45-PE,
anti-cytokeratin [5, 6, 8, 17, 19]-FITC (both from Dako, Hamburg, Ger-
many); anti-CXCR4-PE (R&D systems, Minneapolis, MN); anti-ESA-
APC (biomeda, Foster City, CA); or appropriate isotype-matched con-
trol antibodies. Samples were analyzed by flow cytometry, using
a FACSCalibur (Becton Dickinson, Heidelberg, Germany), and data
were analyzed with CELLQuest Pro software (Becton Dickinson).
Transmigration Assay
A total of 5 3 105 isolated tumor cells were resuspended in 250 ml of
DMEM containing 1%FCS and placed in the upper chamber of amod-
ified Boyden chamber filled with Matrigel (BioCoat invasion assay, 8
mm pore size, Becton Dickinson Labware, Two Oak Park, Bedford,
MA). The upper chamber was placed in a 24-well culture dish contain-
ing 500 ml of the medium described above supplemented with 100 ng/
ml SDF-1 (PeproTech EC). After 24 hr of incubation at 37C, transmi-
grated cells were pelleted and counted using a Neubauer chamber.
Cell-Cycle Analysis
L3.6 pl cells were cultivated under normal conditions as described
above. Gemcitabine was added at a concentration of 100 ng/ml for
24 hr, and cells were then pulsed with BrdU (BD) for 2 hr. In some
experiments, gemcitabine was withdrawn after 24 hr, and normal
culture medium was added for another 24 hr. Cell-cycle analysis was
performed with the BrdU flow cytometry kit (BD) according to the
manufacturer’s instructions.
Animals and Orthotopic Implantation
of Tumor Cells
Athymic 8- to 10-week-old mice (NMRI-nu/nu) were purchased from
Charles River (Sulzfeld, Germany). The mice were housed and main-322 Cell Stem Cell 1, 313–323, September 2007 ª2007 Elsevitained in laminar flow cabinets under specific pathogen-free condi-
tions in accordance with current regulations and standards of the Gov-
ernment of Upper Bavaria, Germany. The mice were used in
accordance with institutional guidelines when they were 8–12 weeks
of age. To generate tumors, suspensions consisting of single cells
with >90% viability were orthotopically injected into the pancreas as
described previously (Bruns et al., 1999). The size and weight of the
primary pancreatic tumors, the incidence of regional (celiac and
para-aortal) lymph node metastasis, and the number of liver meta-
stases were recorded. Histopathology confirmed the nature of the dis-
ease. In some experiments, 7 days after implantation of tumor cells
into the pancreas, mice were randomized to treatment with twice-
a-week intraperitoneal injections of gemcitabine for 21 days at 125
mg/kg or vehicle.
Histological Analysis
For histological evaluation of the tumors, one part of the tumor tissue
was fixed in formalin and embedded in paraffin. Another part of the tu-
mor was embedded in O.C.T. compound (Sakura Finetek, Torrance,
CA) and stored at 80C. Liver metastases were counted following
staining of liver sections for cytokeratin 5, 6, 8, 17, 19 (Dako) and he-
malaun (Sigma). For the detection of CSC, sections were double
stained with APC-labeled CD133 monoclonal antibodies (Miltenyi)
and antibodies against cytokeratin or CXCR4. Nuclei were identified
by DAPI (Vector Labs, Burlingame, CA). CSC frequency was defined
as the number of CD133+ cells per high-power field. All images were
generated on a Zeiss LSM 510 meta confocal laser scanning micro-
scope.
Statistical Analysis
Results for continuous variables are expressed as means ± standard
deviation. Treatment groups were compared with the independent
samples’ t test. In case of nonnormal distribution, the Mann-Whitney
U test was used. Pairwise multiple comparisons were performed
with the one-way ANOVA (two-sided) with Bonferroni adjustment.
P values < 0.05 were considered statistically significant. All analyses
were performed with SPSS 11.5 (SPSS Inc., Chicago, IL).
Supplemental Data
Supplemental Data include one table and four figures and can be
found with this article online at http://www.cellstemcell.com/cgi/
content/full/1/3/313/DC1/.
ACKNOWLEDGMENTS
We are indebted to Christoph von Hesler, Anne Tischer, Michael Eder,
Martin Luckner, and Karin Nispel for their excellent technical assis-
tance. This work was supported by the Deutsche Forschungsgemein-
schaft (FOR 501: HE 3044/2-2 to C.H., GU 489/3-1 for M.G., and KFO
128/1-1 to C.J.B.). This report includes unpublished data that were
generated during the doctoral thesis of Patrick C. Hermann at the
Medical School of the Ludwig-Maximilians-University, Munich.
Received: February 21, 2007
Revised: May 11, 2007
Accepted: June 12, 2007
Published: September 12, 2007
REFERENCES
Ahlgren, J.D. (1996). Chemotherapy for pancreatic carcinoma. Cancer
78, 654–663.
Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and
Clarke, M.F. (2003). Prospective identification of tumorigenic breast
cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983–3988.
Bachelder, R.E., Wendt, M.A., and Mercurio, A.M. (2002). Vascular en-
dothelial growth factor promotes breast carcinoma invasion in aner Inc.
Cell Stem Cell
Cancer Stem Cells in Tumor Metastasisautocrine manner by regulating the chemokine receptor CXCR4. Can-
cer Res. 62, 7203–7206.
Barnett, S.C., Robertson, L., Graham, D., Allan, D., and Rampling, R.
(1998). Oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells
transformed with c-myc and H-ras form high-grade glioma after ste-
reotactic injection into the rat brain. Carcinogenesis 19, 1529–1537.
Bruns, C.J., Harbison, M.T., Kuniyasu, H., Eue, I., and Fidler, I.J.
(1999). In vivo selection and characterization of metastatic variants
from human pancreatic adenocarcinoma by using orthotopic implan-
tation in nude mice. Neoplasia 1, 50–62.
Burger, J.A., and Kipps, T.J. (2006). CXCR4: a key receptor in the
crosstalk between tumor cells and their microenvironment. Blood
107, 1761–1767.
Clarke, M.F., Dick, J.E., Dirks, P.B., Eaves, C.J., Jamieson, C.H.,
Jones, D.L., Visvader, J., Weissman, I.L., and Wahl, G.M. (2006). Can-
cer stem cells–perspectives on current status and future directions:
AACR workshop on cancer stem cells. Cancer Res. 66, 9339–9344.
Dalerba, P., Cho, R.W., and Clarke, M.F. (2007). Cancer stem cells:
models and concepts. Annu. Rev. Med. 58, 267–284.
Denham, M., Huynh, T., Dottori, M., Allen, G., Trounson, A., and
Mollard, R. (2006). Neural stem cells express non-neural markers
during embryoid body coculture. Stem Cells 24, 918–927.
Dick, J.E. (2005). Acute myeloid leukemia stem cells. Ann. N Y Acad.
Sci. 1044, 1–5.
Dontu, G., Abdallah, W.M., Foley, J.M., Jackson, K.W., Clarke, M.F.,
Kawamura, M.J., and Wicha, M.S. (2003). In vitro propagation and
transcriptional profiling of human mammary stem/progenitor cells.
Genes Dev. 17, 1253–1270.
Fargeas, C.A., Corbeil, D., and Huttner, W.B. (2003). AC133 antigen,
CD133, prominin-1, prominin-2, etc.: prominin family gene products
in need of a rational nomenclature. Stem Cells 21, 506–508.
He, X.C., Yin, T., Grindley, J.C., Tian, Q., Sato, T., Tao, W.A., Dirisina,
R., Porter-Westpfahl, K.S., Hembree, M., Johnson, T., et al. (2007).
PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat.
Genet. 39, 189–198.
Jemal, A., Tiwari, R.C., Murray, T., Ghafoor, A., Samuels, A., Ward, E.,
Feuer, E.J., and Thun, M.J. (2004). Cancer statistics, 2004. CA Cancer
J. Clin. 54, 8–29.
Jordan, C.T., Guzman, M.L., and Noble, M. (2006). Cancer stem cells.
N. Engl. J. Med. 355, 1253–1261.
Kim, C.F., Jackson, E.L., Woolfenden, A.E., Lawrence, S., Babar, I.,
Vogel, S., Crowley, D., Bronson, R.T., and Jacks, T. (2005). Identifica-
tion of bronchioalveolar stem cells in normal lung and lung cancer. Cell
121, 823–835.
Kucia, M., Reca, R., Miekus, K., Wanzeck, J., Wojakowski, W.,
Janowska-Wieczorek, A., Ratajczak, J., and Ratajczak, M.Z. (2005).
Trafficking of normal stem cells and metastasis of cancer stem cells
involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis.
Stem Cells 23, 879–894.
Li, C., Heidt, D.G., Dalerba, P., Burant, C.F., Zhang, L., Adsay, V.,
Wicha, M., Clarke, M.F., and Simeone, D.M. (2007). Identification of
pancreatic cancer stem cells. Cancer Res. 67, 1030–1037.
Loetscher, P., Moser, B., and Baggiolini, M. (2000). Chemokines and
their receptors in lymphocyte traffic and HIV infection. Adv. Immunol.
74, 127–180.
Matano, E., Tagliaferri, P., Libroia, A., Damiano, V., Fabbrocini, A.,
De Lorenzo, S., and Bianco, A.R. (2000). Gemcitabine combined
with continuous infusion 5-fluorouracil in advanced and symptomatic
pancreatic cancer: a clinical benefit-oriented phase II study. Br. J.
Cancer 82, 1772–1775.
Moll, R. (1998). Cytokeratins asmarkers of differentiation in the diagno-
sis of epithelial tumors. Subcell. Biochem. 31, 205–262.
Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E.,
McClanahan, T., Murphy, E., Yuan, W., Wagner, S.N., et al. (2001).Cell SInvolvement of chemokine receptors in breast cancer metastasis.
Nature 410, 50–56.
O’Brien, C.A., Pollett, A., Gallinger, S., and Dick, J.E. (2007). A human
colon cancer cell capable of initiating tumour growth in immunodefi-
cient mice. Nature 445, 106–110.
Passegue, E., Jamieson, C.H., Ailles, L.E., and Weissman, I.L. (2003).
Normal and leukemic hematopoiesis: are leukemias a stem cell disor-
der or a reacquisition of stem cell characteristics? Proc. Natl. Acad.
Sci. USA 100 (Suppl 1), 11842–11849.
Peichev, M., Naiyer, A.J., Pereira, D., Zhu, Z., Lane, W.J., Williams, M.,
Oz, M.C., Hicklin, D.J., Witte, L., Moore, M.A., and Rafii, S. (2000).
Expression of VEGFR-2 and AC133 by circulating humanCD34(+) cells
identifies a population of functional endothelial precursors. Blood 95,
952–958.
Prindull, G. (2005). Hypothesis: cell plasticity, linking embryonal stem
cells to adult stem cell reservoirs and metastatic cancer cells? Exp.
Hematol. 33, 738–746.
Ricci-Vitiani, L., Lombardi, D.G., Pilozzi, E., Biffoni, M., Todaro, M.,
Peschle, C., and De Maria, R. (2007). Identification and expansion of
human colon-cancer-initiating cells. Nature 445, 111–115.
Rosenberg, L. (1997). Treatment of pancreatic cancer. Promises and
problems of tamoxifen, somatostatin analogs, and gemcitabine. Int.
J. Pancreatol. 22, 81–93.
Rothenberg, M.L., Abbruzzese, J.L., Moore, M., Portenoy, R.K.,
Robertson, J.M., and Wanebo, H.J. (1996). A rationale for expanding
the endpoints for clinical trials in advanced pancreatic carcinoma.
Cancer 78, 627–632.
Saur, D., Seidler, B., Schneider, G., Algul, H., Beck, R., Senekowitsch-
Schmidtke, R., Schwaiger, M., and Schmid, R.M. (2005). CXCR4
expression increases liver and lung metastasis in a mouse model of
pancreatic cancer. Gastroenterology 129, 1237–1250.
Schneider, G.P., Salcedo, R., Dong, H.F., Kleinman, H.K., Oppenheim,
J.J., and Howard, O.M.Z. (2002). Suradista NSC 651016 inhibits the
angiogenic activity of CXCL12-stromal cell-derived factor 1{alpha}.
Clin. Cancer Res. 8, 3955–3960.
Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T.,
Henkelman, R.M., Cusimano, M.D., and Dirks, P.B. (2004). Identifica-
tion of human brain tumour initiating cells. Nature 432, 396–401.
Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E.J., and
Krek, W. (2003). Chemokine receptor CXCR4 downregulated by von
Hippel-Lindau tumour suppressor pVHL. Nature 425, 307–311.
Uchida, N., Buck, D.W., He, D., Reitsma, M.J., Masek, M., Phan, T.V.,
Tsukamoto, A.S., Gage, F.H., and Weissman, I.L. (2000). Direct isola-
tion of human central nervous system stem cells. Proc. Natl. Acad. Sci.
USA 97, 14720–14725.
Warshaw, A.L., and Fernandez-del Castillo, C. (1992). Pancreatic car-
cinoma. N. Engl. J. Med. 326, 455–465.
Yin, A.H., Miraglia, S., Zanjani, E.D., Almeida-Porada, G., Ogawa, M.,
Leary, A.G., Olweus, J., Kearney, J., and Buck, D.W. (1997). AC133,
a novel marker for human hematopoietic stem and progenitor cells.
Blood 90, 5002–5012.
Zagzag, D., Krishnamachary, B., Yee, H., Okuyama, H., Chiriboga, L.,
Ali, M.A., Melamed, J., and Semenza, G.L. (2005). Stromal cell-derived
factor-1alpha and CXCR4 expression in hemangioblastoma and
clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function
induces expression of a ligand and its receptor. Cancer Res. 65,
6178–6188.
Zeelenberg, I.S., Ruuls-Van Stalle, L., and Roos, E. (2003). The chemo-
kine receptor CXCR4 is required for outgrowth of colon carcinoma
micrometastases. Cancer Res. 63, 3833–3839.
Zou, Y.R., Kottmann, A.H., Kuroda, M., Taniuchi, I., and Littman, D.R.
(1998). Function of the chemokine receptor CXCR4 in haematopoiesis
and in cerebellar development. Nature 393, 595–599.tem Cell 1, 313–323, September 2007 ª2007 Elsevier Inc. 323
